Key result
Reduced baseline omentin-1 levels were significantly associated with a higher incidence of major adverse cardiovascular events and major adverse limb events at 12 months in diabetic patients with peripheral artery disease undergoing endovascular revascularization.
Why the study?
Omentin-1 levels are reduced in T2DM patients with PAD and inversely related to severity, but their relationship with outcomes after endovascular revascularization in CLTI was unknown.
Do baseline omentin-1 levels predict major cardiovascular and limb events in T2DM patients with PAD and CLTI undergoing endovascular revascularization?
Cohort (n=207)
Non-randomized
No
Do baseline omentin-1 levels predict major cardiovascular and limb events in T2DM patients with PAD and CLTI undergoing endovascular revascularization?
Reduced baseline omentin-1 levels independently predict worse cardiovascular and limb outcomes in diabetic patients with chronic limb-threatening ischemia undergoing endovascular revascularization.
Answers are grounded in this paper and cite their sources.
May support future risk stratification in diabetic PAD; leaves open validation before clinical use.
BACKGROUND: Cardiovascular complications represent the major cause of morbidity and mortality of type 2 diabetes mellitus (T2DM) patients. In particular, peripheral artery disease (PAD) represents a frequent T2DM vascular complication and a risk factor for the development of major adverse cardiovascular events (MACE). Among adipokines, omentin-1 serum levels are reduced in T2DM patients with PAD and are inversely related to disease severity. OBJECTIVE: To study the relationship between omentin-1 levels, at baseline, with outcomes after endovascular procedures in T2DM patients with PAD and chronic limb-threatening ischemia (CLTI). RESEARCH DESIGN AND METHODS: We enrolled for our prospective non-randomized study, 207 T2DM patients with PAD and CLTI, requiring revascularization. Omentin-1 serum levels were collected before revascularization and patients incidence outcomes were evaluated at 1, 3, 6 and 12 months. RESULTS: Omentin-1 was reduced in patients with more severe disease (27.24 ± 4.83 vs 30.82 ± 5.48 ng/mL, p < 0.001). Overall, 84 MACE and 96 major adverse limb events (MALE) occurred during the 12-month follow-up. We observed that omentin-1 levels were lower in patients with MACE (26.02 ± 4.05 vs 31.33 ± 5.29 ng/mL, p < 0.001) and MALE (26.67 ± 4.21 vs 31.34 ± 5.54 ng/mL, p < 0.001). The association between omentin-1, MACE and MALE remained significant after adjusting for major risk factors in a multivariate analysis. Receiver operating characteristics (ROC) curve using omentin-1 levels predicted incidence events (area under the curve = 0.80). CONCLUSIONS: We demonstrated that reduced omentin-1 levels, at baseline, are related with worse vascular outcomes in T2DM patients with PAD and CLTI undergoing an endovascular procedure.
No takes yet. Share an insight, caveat, or question.
Biscetti et al. (2020) conducted a cohort in Type 2 diabetes mellitus with peripheral artery disease and chronic limb-threatening ischemia (n=207). Baseline omentin-1 serum levels vs. Higher vs lower levels was evaluated on Baseline omentin-1 levels in patients with vs without major adverse cardiovascular events (MACE) at 12 months (p=<0.001). Reduced baseline omentin-1 levels were significantly associated with a higher incidence of major adverse cardiovascular events and major adverse limb events at 12 months in diabetic patients with peripheral artery disease undergoing endovascular revascularization.
Synapse has enriched 10 related papers. Consider them for comparative context: